|
Synonyms: ALN-81890 | BRII-835 | VIR-2218
Compound class:
Nucleic acid
Comment: Elebsiran (VIR-2218) is a N-acetylgalactosamine (GalNAc)-conjugated small interfering RNA (siRNA) that is designed to target hepatitis B virus (HBV) RNA as a mechanism to combat chronic HBV infection [2]. The nucleotides are chemically modified (2'-O-methyl/2'-MOE and 2'-deoxy-2'-fluoro/2'-F monomers), with a mixed phosphorothioate/phosphate backbone.
|
| References |
|
1. Gane E, Lim YS, Kim JB, Jadhav V, Shen L, Bakardjiev AI, Huang SA, Cathcart AL, Lempp FA, Janas MM et al.. (2023)
Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: Results from randomized clinical trials. J Hepatol, 79 (4): 924-932. [PMID:37290591] |
|
2. Gupta SV, Fanget MC, MacLauchlin C, Clausen VA, Li J, Cloutier D, Shen L, Robbie GJ, Mogalian E. (2021)
Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection. Drugs R D, 21 (4): 455-465. [PMID:34741731] |
|
3. Yuen MF, Lim YS, Yoon KT, Lim TH, Heo J, Tangkijvanich P, Tak WY, Thanawala V, Cloutier D, Mao S et al.. (2024)
VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study. Lancet Gastroenterol Hepatol, 9 (12): 1121-1132. [PMID:39389081] |